Fluoxetine Hydrochloride; Olanzapine Patent Expiration
Fluoxetine Hydrochloride; Olanzapine is Used for acute treatment of treatment-resistant depression in adults. It was first introduced by Eli Lilly And Co
Fluoxetine Hydrochloride; Olanzapine Patents
Given below is the list of patents protecting Fluoxetine Hydrochloride; Olanzapine, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Symbyax | US6960577 | Combination therapy for treatment of refractory depression |
Nov 01, 2017
(Expired) | Lilly |
| Symbyax | US5945416 | Method for treating pain |
Mar 24, 2017
(Expired) | Lilly |
A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Fluoxetine Hydrochloride; Olanzapine's patents.
Latest Legal Activities on Fluoxetine Hydrochloride; Olanzapine's Patents
Given below is the list recent legal activities going on the following patents of Fluoxetine Hydrochloride; Olanzapine.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Patent Issue Date Used in PTA Calculation Critical | 01 Nov, 2005 | US6960577 |
| Recordation of Patent Grant Mailed Critical | 01 Nov, 2005 | US6960577 |
| Issue Notification Mailed Critical | 12 Oct, 2005 | US6960577 |
| Receipt into Pubs | 06 Oct, 2005 | US6960577 |
| Dispatch to FDC | 05 Oct, 2005 | US6960577 |
| Application Is Considered Ready for Issue Critical | 13 Aug, 2005 | US6960577 |
| Issue Fee Payment Verified Critical | 05 Jul, 2005 | US6960577 |
| Issue Fee Payment Received Critical | 05 Jul, 2005 | US6960577 |
| Mail Examiner's Amendment | 02 Jun, 2005 | US6960577 |
| Mail Notice of Allowance Critical | 02 Jun, 2005 | US6960577 |
Fluoxetine Hydrochloride; Olanzapine's Family Patents
Explore Our Curated Drug Screens
Fluoxetine Hydrochloride; Olanzapine Generic API Manufacturers
Several generic applications have been filed for Fluoxetine Hydrochloride; Olanzapine. The first generic version for Fluoxetine Hydrochloride; Olanzapine was by Teva Pharmaceuticals Usa and was approved on Jun 19, 2012. And the latest generic version is by Teva Pharmaceuticals Usa and was approved on Mar 25, 2013.
Given below is the list of companies who have filed for Fluoxetine Hydrochloride; Olanzapine generic, along with the locations of their manufacturing plants worldwide.
1. ENDO OPERATIONS
Endo Operations Ltd has filed for 5 different strengths of generic version for Fluoxetine Hydrochloride; Olanzapine. All of these versions come by the name OLANZAPINE AND FLUOXETINE HYDROCHLORIDE. Given below are the details of the strengths of this generic introduced by Endo Operations.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| EQ 25MG BASE; EQ 6MG BASE | capsule | Prescription | ORAL | AB | Nov 2, 2012 |
| EQ 25MG BASE; EQ 3MG BASE | capsule | Prescription | ORAL | AB | Nov 2, 2012 |
| EQ 25MG BASE; EQ 12MG BASE | capsule | Prescription | ORAL | AB | Nov 2, 2012 |
| EQ 50MG BASE; EQ 6MG BASE | capsule | Prescription | ORAL | AB | Nov 2, 2012 |
| EQ 50MG BASE; EQ 12MG BASE | capsule | Prescription | ORAL | AB | Nov 2, 2012 |
2. EPIC PHARMA LLC
Epic Pharma Llc has filed for 5 different strengths of generic version for Fluoxetine Hydrochloride; Olanzapine. All of these versions come by the name OLANZAPINE AND FLUOXETINE HYDROCHLORIDE. Given below are the details of the strengths of this generic introduced by Epic Pharma Llc.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| EQ 25MG BASE; EQ 6MG BASE | capsule | Prescription | ORAL | AB | Nov 16, 2012 |
| EQ 50MG BASE; EQ 6MG BASE | capsule | Prescription | ORAL | AB | Nov 16, 2012 |
| EQ 25MG BASE; EQ 12MG BASE | capsule | Prescription | ORAL | AB | Nov 16, 2012 |
| EQ 50MG BASE; EQ 12MG BASE | capsule | Prescription | ORAL | AB | Nov 16, 2012 |
| EQ 25MG BASE; EQ 3MG BASE | capsule | Prescription | ORAL | AB | Nov 16, 2012 |
3. TEVA PHARMS
Teva Pharmaceuticals Usa has filed for 5 different strengths of generic version for Fluoxetine Hydrochloride; Olanzapine. All of these versions come by the name OLANZAPINE AND FLUOXETINE HYDROCHLORIDE. Given below are the details of the strengths of this generic introduced by Teva Pharms.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| EQ 50MG BASE; EQ 12MG BASE | capsule | Prescription | ORAL | AB | Jun 19, 2012 |
| EQ 25MG BASE; EQ 6MG BASE | capsule | Prescription | ORAL | AB | Jun 19, 2012 |
| EQ 25MG BASE; EQ 12MG BASE | capsule | Prescription | ORAL | AB | Jun 19, 2012 |
| EQ 50MG BASE; EQ 6MG BASE | capsule | Prescription | ORAL | AB | Jun 19, 2012 |
| EQ 25MG BASE; EQ 3MG BASE | capsule | Prescription | ORAL | AB | Mar 25, 2013 |